Trials / Completed
CompletedNCT03267303
A Study to Evaluate the Safety and Efficacy of TS-091 in Patients with Narcolepsy
A Phase II, Double-blind, Parallel-group Comparative Study 2 of TS-091 in Patients with Narcolepsy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Taisho Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 16 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the efficacy and safety after administration of TS-091 compared with placebo in patients with narcolepsy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TS-091 5mg | Orally taken once daily for 3 weeks |
| DRUG | TS-091 10mg | Orally taken once daily for 3 weeks |
| DRUG | Placebo | Orally taken once daily for 3 weeks |
Timeline
- Start date
- 2017-10-31
- Primary completion
- 2018-12-13
- Completion
- 2019-08-08
- First posted
- 2017-08-30
- Last updated
- 2025-02-28
Locations
2 sites across 2 countries: Japan, South Korea
Source: ClinicalTrials.gov record NCT03267303. Inclusion in this directory is not an endorsement.